AbbVie makes a play for psychiatric treatments with $2bn Gilgamesh collaboration
The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.
Psychiatric disorders
TREAT California embarks on plan to earn $5bn for psychedelic research
FDA approves Janssen’s twice-yearly antipsychotic for schizophrenia
Major depressive disorder: why does it affect women more?
Biogen and Sage Therapeutics to co-develop depression and tremor therapies
Janssen’s esketamine nasal spray not recommended by NICE for NHS use
FDA approves Secuado patch for Schizophrenia
FDA greenlight for esketamine sheds light on ketamine’s potential
